Transforming How the Immune System Targets and Fights Cancer to Promote Survival NASDAQ: PDSB September 2024 Precision Designed Science For Immunotherapy Forward-Looking Statements This communication contains forward-loo

Transforming How the Immune System Targets and Fights Cancer to Promote

Survival NASDAQ: PDSB September 2024 Precision Designed Science For Immunotherapy

Forward-Looking Statements This communication contains forward-looking

statements (including within the meaning of Section 27E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the

"Company") and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company's

management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions and

include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," "forecast," "guidance", "outlook" and other similar expressions among others. Forward-looking

statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as

a result of various factors, including, without limitation: the Company's ability to protect its intellectual property rights; the Company's anticipated capital requirements, including the Company's anticipated cash runway and the Company's

current expectations regarding its plans for future equity financings; the Company's dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that

raising such additional capital may restrict the Company's operations or require the Company to relinquish rights to the Company's technologies or product candidates; the Company's limited operating history in the Company's current line of

business, which makes it difficult to evaluate the Company's prospects, the Company's business plan or the likelihood of the Company's successful implementation of such business plan; the timing for the Company or its partners to initiate the

planned clinical trials for PDS01ADC, Versamune HPV and other Versamune and lnfectimune based product candidates; the future success of such trials; the successful implementation of the Company's research and development programs and

collaborations, including any collaboration studies concerning PDS01ADC, Versamune HPV and other Versamune and lnfectimune based product candidates and the Company's interpretation of the results and findings of such programs and

collaborations and whether such results are sufficient to support the future success of the Company's product candidates; the success, timing and cost of the Company's ongoing clinical trials and anticipated clinical trials for the Company's

current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company's ability to fully fund its disclosed clinical trials, which assumes no material

changes to the Company's currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or

data), which are not necessarily indicative of the final results of the Company's ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early

clinical results from its clinical development programs and any collaboration studies; to aid in the development of the Versamune platform; and other factors, including legislative, regulatory, political and economic developments not within

the Company's control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and

elsewhere, including the risk factors included in the Company's annual, quarterly and periodic reports filed with the Securities and Exchange Commission ("SEC"). The forward-looking statements are made only as of the date of this press

release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events

or otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale

would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Versamune and lnfectimune are registered trademarks of PDS Biotechnology Corporation. KEYTRUDA is a registered

trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Late-Stage Head and Neck Cancer Program as Value Catalyst Potent Long-Lasting

"Memory" T Cells High-Value Lead Program with strong KOL support Promising Phase 2 Data Phase 3 Design 30 months median Overall Survival (mOS) 77% Disease Control Rate (DCR) Well tolerated: 9% Grade 3, 1% Grade 4 AE Targeted

immunotherapy in HPV16-positive Recurrent and/or Metastatic Head & Neck Squamous Cell Carcinoma (R/M HNSCC) Fast Track designation for Versamune HPV in HNSCC Alignment with FDA on Phase 3 study design Trial initiation planned for

Q4-2024 Induction of right type and quantity of potent tumor-accumulating killer T cells observed in comprehensive preclinical and human studies

Significant and Growing Market Potential in HPV16-positive HNSCC HPV16 to Drive

Increased HNSCC Incidence Rates & Exceed 50% of all HNSCC by mid 2030s1 Current US annual incidence of HPV16-positive HNSCC = 18,000 (~35-40% of all HNSCC)2-4 Incidence of locally advanced, unresectable, metastatic HPV16+ HNSCC =

13,6004-7 Versamune HPV US Market Potential = $2-3B* EU HPV+ HNSCC incidence and trends similar to US *Independent Market Research, Triangle Research Group

Approx. 13,600 US Patients Annually with Advanced HPV16-positive

HNSCC Epidemiology-Based Estimate of Addressable Population: HNSCC8 U.S. Other Head and Neck Cancersa,d U.S. HPV Positivec HPV16 Genotypeb Locally Advanced, Unresectable and Metastaticd ~3,300 (56%) ~5,900 (82%) ~7,200

(22%) ~32,500 U.S. Oropharyngeal Cancer in 2024a U.S. HPV Positivea HPV16 Genotypeb Locally Advanced, Unresectable and Metastaticd ~10,300 (84%) ~12,300 (83%) ~14,800 (70%) ~20,805 Oropharyngeal Cancer (OPC) Growing Market - Key

Opportunity Other HNSCC (non-OPC) Focus of bi-specific EGFR Inhibitors *ICD-O-3 site codes C01.9, C02.4, C02.8, C05.1, C05.2, C09.0, C09.1, C09.8, C09.9, C10.0, C10.1, C10.2, C10.3, C10.4, C10.8, C10.9, C14.0, C14.2, and C14.8; **Other

head and neck cancers include sinonasal, oral cavity, laryngeal, and nasopharyngeal with calculations based on weighted average with share of total head and neck cancers Sources: aCDC.gov accessed January 2022; bSaraiya, Mona et al. "US

assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines." Journal of the National Cancer Institute vol. 107,6 djv086. 29 Apr. 2015, doi:10.1093/jnci/djv086; SEER, Accessed February 2024; cIsayeva, et al., Human

Papillomavirus in Non-Oropharyngeal Head and Neck Cancers: A Systematic Review (2012).; dSEER, Accessed February 2024; dMazul, A., et al., Disparities in head and neck cancer incidence and trends by race/ethnicity and sex; *Independent

Market Research, Triangle Research Group

Significant Unmet Needs Remain in Recurrent/Metastatic HPV16 HNSCC

KEYTRUDA KEYTRUDA Plus Chemo Chemotherapy + EGFR Inhibitor Objective Response Rate (ORR) 19% 36% 35% Progression Free Survival (PFS) 3.2 mos 5.0 mos 5.0 mos Median Overall Survival (OS) 12.3 mos 13.6 mos 10.3

mos Treatment Related Grade 3+ Toxicities 17% 72% 69% HPV16-Specificity: Need Targeted treatment option to address the growing population of HPV16-positive HNSCC and improve outcomes Improved Survival: Need Novel MOA that provides

enhanced survival Improved Durability: Need Novel MOA that is clinically effective and provides more durable (long-term) responses. Improved Safety: Need Safe treatments that may be used with or in place of current standard of care and

chemotherapy Oncologists10 - Stated Unmet Medical Needs in HPV16 HNSCC * No control or comparative studies have been conducted between immune checkpoint inhibitors, EGFR inhibitors, chemotherapy and Versamune HPV Standard of Care for

Recurrent or Metastatic HNSCC - Published Results*9

Versamune HPV may Address a Significant Unmet Need in R/M

HNSCC KEYNOTE-0489 Pembrolizumab EGFR antibody (cetuximab) + chemotherapy LEAP-01011 Pembrolizumab Pembrolizumab + lenvatinib Improved ORR and PFS Have Not Resulted in FDA-Required Improved Patient Survival ORR = Objective Response

Rate; PFS = Progression Free Survival; OS = Overall Survival

VERSATILE-002: A Global Phase 2 Study of Versamune HPV and Pembrolizumab in

Subjects with HPV16-positive Recurrent/Metastatic HNSCC Partner StudyDesign Open-label, non-randomized, adaptive design study 31 sites in US and EU 2 Cohorts: ICI Na ve ICI Resistant Enrollment complete Key Entry Criteria for ICI

Na ve Subjects Recurrent or metastatic HNSCC 18 years of age HPV16-positive tumor Combined positive score (CPS) 1 Versamune HPV 5 doses: 1 mL Subcutaneous injection at Cycles 1, 2, 3, 4 & 12) Pembrolizumab (KEYTRUDA ) 200mg IV

Q3W up to 35 Cycles (2 years) Study Treatment Primary: Best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) per RECIST v1.1 Key Secondary: Overall Survival (OS) Progression Free Survival

(PFS) per RECIST v1.1 Safety and tolerability Endpoints Fast Track Designation Study Evaluating Effects of Versamune HPV Attributes on Clinical Responses

VERSATILE-002: Most Patients Had Recurrent Disease and CPS Score

1-19 Historical Responses9 Published data reports lower ORR, PFS and OS with pembrolizumab in patients with CPS 1-19 vs. CPS 20 Published data reports lower responses in patients with recurrent disease Data on File: Data represents a

17May2024 data cut Key Demographics and Treatment Exposure12 Demographic/Baseline Characteristic Efficacy Population (N=53) Age, Median (Min, Max) 64.0 (46, 83) Sex, n (%) Male Female 49 (92.5) 4 (7.5) Race, n (%) Asian Black

or African American White Other 1 (1.9) 1 (1.9) 50 (94.3) 1 (1.9) ECOG, n (%) 0 1 30 (56.6) 23 (43.4) CPS, n (%) 1-19 20 32 (60.4) 21 (39.6) Prior Therapy*, n (%) No Prior Therapy Chemotherapy Only Chemotherapy

+ Radiation Therapy 10 (18.9) 3 (5.7) 40 (75.5) Lower pembrolizumab responses

Percent Change from Baseline in Target

Lesions -50 -25 25 50 75 100 0 -75 -100 -125 CPS Group 1-19 20 CPS Group Response Complete Response (CR) 5/53 9.4% Partial Response (PR) 14/53 26.4% Stable Disease (SD) 22/53 41.5% Progressive Disease (PD) 9/53 17.0%

Treatment Ongoing Confirmed Objective Response Rate (ORR) Based on Investigator Assessment Per RECIST v1.1 Data on File: Data represents a 17May2024 data cut Best Percentage Change from Baseline in Target Lesions (mITT

population) 11/53 (21%) of patients had 90-100% tumor shrinkage Versamune HPV + ICI Promoted Deep Tumor Regression in Several Patients Independent of CPS Score; Confirmed Disease Control Rate of 77.4%12

Extended Disease Control Observed in Majority of Patients Confirmed Objective

Response Rate (ORR) Based on Investigator Assessment Per RECIST v1.1 Data on File: Data represents a 17May2024 data cut Best Percentage Change from Baseline in Target Lesions Promising Long-Lasting Immune Response with CR, PR and SD

Maintained Long-Term12 Percent Change from Baselinein Target Lesions Time of Assessment

(Months) 0 2 4 6 8 10 12 14 16 18 20 22 24 1 3 5 7 9 11 13 15 17 19 21 23 -125 -100 150 175 200 225 50 75 100 125 -50 -25 0 25 -75 Response Complete Response Partial Response Stable

Disease Progressive Disease Treatment Ongoing

Survival Exceeds Historical Median Survival in Majority of Patients Confirmed

Objective Response Rate (ORR) Based on Investigator Assessment Per RECIST v1.1 Data on File: Data represents a 17May2024 data cut Swimmer Plot of Overall Survival and Progression Free

Survival12 Subjects 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 Overall Survival (Months) Complete Response Partial Response Stable Disease Progressive Disease Not Evaluable Survival

Follow-up Death Withdrew Consent Lost to Follow-up

Fraction 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 0.0 0.2 0.4 0.6 0.8 1.0 Censored Ongoing (N=27) Censored Discontinued (N=8) Data on File: Represents a 17May2024 data cut Discontinued: N=2 Lost to

follow up; N=6 withdrawn consent; Ongoing: Patients ongoing and awaiting next clinical assessment Median Overall Survival of 30 Months12 Multiple Patients Approaching 3 Years of Survival 53 (0) 50 (3) 46 (6) 42 (8) 40 (8) 37

(10) 34 (11) 32 (11) 23 (13) 20 (13) 16 (15) 14 (15) 9 (16) 8 (16) 7 (16) 5 (18) 3 (18) 1 (18) 0 (18) Number at Risk Median OS, months (95% CI) = 30.0 (19.7, NE) Median follow up (months) = 16

Versamune HPV Plus Pembrolizumab Appears to be Well Tolerated Protocol

stipulates 5 subcutaneous injections of Versamune HPV: 4 injections over 2 months and a final injection after an additional 6 months *Grade 3 Combination-TRAE were: Fatigue (2), Rash, Alanine aminotransferase increased, Blood alkaline

phosphatase increased, Lymphocyte count decreased, Autoimmune colitis, Colitis, Headache, Acute kidney injury, Hyponatremia, Hyperglycemia, **Grade 4 Combination-TRAE: encephalitis (case recorded approx. one year after last Versamune HPV

dose) * TRAE = Treatment Related Adverse Event Data on File: Data represents a 17May2024 data cut, and includes ICI na ve and ICI resistant HPV16-positive patients 8/87 (9%) Patients had a Grade 3 TRAE*; 1/87 (1%) had a Grade 4 TRAE**

TRAEs by Grade n (%) Any Combination TRAE 76 (87.4) Grade 1 40 (46.0) Grade 2 26 (29.9) Grade 3 8 (9.2) Grade 4 1 (1.1) Grade 5 0 Non-Injection Site TRAEs 5% n (%) Fatigue 30 (34.5) Headache 13 (14.9) Diarrhea 10

(11.5) Pruritis 9 (10.3) Rash 7 (8.0) Malaise 6 (6.9) Pyrexia 6 (6.9) Pain 5 (5.7) Cough 5 (5.7)

VERSATILE-002 Summary of Results Study has met primary ORR endpoint by RECIST

v1.1 in ICI na ve patients ORR by Investigator Assessment: 36% (CPS 1) and 48% (CPS 20) 21% of patients had 90-100% shrinkage of their tumors Versamune HPV + KEYTRUDA may significantly impact DCR and OS in first line treatment of

recurrent/metastatic HPV16 positive head and neck cancer Median OS of 30 months in patients with CPS 1 and in patients with CPS 20 DCR of 77.4% in patients with CPS 1; 81% in patients with CPS 20 PFS of 6.3 months in patients with CPS

1; 14.1 months in patients with CPS 20 Therapy appears to be well tolerated Biomarker and clinical data suggests that Versamune HPV induces the right type and quantity of potent tumor targeting memory T cells that promote patient

VERSATILE-003 First Line Recurrent/Metastatic HNSCC Study Design Interim

Analysis Possible Early Approval Versamune HPV + PDS01ADC + pembrolizumab Q4 2024 Versamune HPV + Pembrolizumab Pembrolizumab Aligned with FDA on Study Design and Initiation Patient Recruitment Patient Recruitment Survival

Follow-up Survival Follow-up Key Eligibility Criteria HPV16-positive HNSCC CPS 1 18 years of age ECOG 0-1 Secondary Endpoints Objective Response Rate (ORR) Disease Control Rate (DCR) Duration of Response (DoR) Progression Free

Survival (PFS) Randomized controlled trial N = 440 2:1 randomization Primary Endpoint Overall Survival (OS) FinalAnalysis FutilityAnalysis

Enabling Q4 2024 Patient Enrollment CRO engaged in site selection and

preparation, investigator agreements, etc. Approx. 130 sites Site locations: US, Canada, UK, EU, Latin America 18-24 months estimated time to full enrollment 18 months estimated time to futility analysis Interim analysis for OS

following event trigger VERSATILE-003 Trial Implementation

Versamune HPV Biomarker Studies (CD8+ T Cells) Stage III and IV locally

advanced cervical cancer patients treated with Versamune HPV and chemoradiotherapy Increase in CD8 T cells in the tumor observed Day 0 to Week 24 - Supports durable responses 91.7% clearance of ctDNA at Week 5 vs 53.1% clearance with CRT

alone - Supports long-term benefit ORR of 100% reported in the first 8 patients, 0% disease recurrence or disease-related deaths in 1-year follow-up Quantity of killer T cells that infiltrated the patient's tumors Quantity of HPV+ tumor

cell DNA circulating in patient blood Clinical: CD8 T Cell Accumulation in Tumor Correlated with Elimination of Circulating Cancer Cells (ctDNA)13,14 Long-Term Tumor Infiltration and Accumulation of Multi-functional CD8+ T

Cells Representative Plot from a Single Patient Week 24 Week 3 Baseline Radiation Oncology Dept. Univ. of Texas MD Anderson Cancer Center

Day 0: HPV16+ TC1 tumor cells were injected into mice Day 12: Resulting tumors

had a size of ~250mm3 (volume) Day 12 : A group of the mice received a single injection of Versamune HPV Day 25: All treated mice had complete regression of their tumors Day 50: 2 sets of mice were injected with the TC1 tumor cells Set

1: Mice previously treated with Versamune HPV Set 2: Na ve mice NOT previously treated with Versamune HPV Only the mice that had been previously treated with Versamune HPV were protected against the cancer with no tumor growth CD8 T